Spring direct naar de hoofdnavigatie of de inhoud

Frits Michiels

Patent attorney

“To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.”
Home / Experts / Frits Michiels

Frits Michiels

  • Life Sciences
  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups. He has worked for V.O. since 2006.

More information about Frits

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

Also see these experts

Wezenbeek, Bart van

Bart van Wezenbeek

  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate

Annemiek Tepper

  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate
More experts

News

Infringement by equivalence

It is one of the most challenging subjects in the field of patents – equivalence. Henri van Kalkeren, patent attorney at V.O., explains: ‘Recent decisions of judges therefore remain relevant to us. It is and remains a relatively grey area.’Continue reading

Platform Formalities Officers increases level of administration

In various European countries, there is a great deal of enthusiasm about the approach and method of the Platform Formalities Officers (PFO). In less than ten years, the PFO has developed into a respected platform. High time to find out a bit more about it. Ronald van Egmond, PFO board member and business support senior […]Continue reading

United Kingdom approves Unified Patent Court

The UK has given its final approval of the new Unified Patent Court (UPC) and the new Unitary Patent on 26 April 2018.Continue reading